Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer

Published:2014-12 Issue:6 Volume:23 Page:710-720
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Dalmau Elsa,Armengol-Alonso Alejandra^ORCID,Muñoz Montserrat,Seguí-Palmer Miguel Ángel

Funder

Novartis S.A.

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference98 articles.

1. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer;Baselga;N Engl J Med,2012

2. The multifaceted mechanism of estradiol and estrogen receptor signaling;Hall;J Biol Chem,2001

3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005

4. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer;Chan;J Clin Oncol,1999

5. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193);Sledge;J Clin Oncol,2003

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Trends in Computer-aided Drug Design for Anti-cancer Drug Discovery;Current Topics in Medicinal Chemistry;2023-12

2. In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer;PLOS ONE;2023-02-09

3. Diagnostic and Prognostic Role of 18F-Fluoroestradiol PET in Metastatic Breast Cancer: The Second Youth of an Older Theranostic Concept;Journal of Clinical Medicine;2022-06-22

4. Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma;Future Oncology;2022-04

5. Discoidin Domain Receptor 2 Expression as Worse Prognostic Marker in Invasive Breast Cancer;The Breast Journal;2022-03-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3